Researchers from St. Jude Children’s Research Hospital have reported the discovery of SJ-3149, a novel selective CK1α degrader being developed for the treatment of cancer.
Researchers from Springworks Therapeutics Inc. and affiliated organizations presented the discovery and preclinical characterization of a novel covalent and irreversible YAP/TAZ-TEAD inhibitor, SWTX-143, being developed for the treatment of mesothelioma.
